Dipal Doshi, President and CEO at Entrada Therapeutics, Inc. (TRDA), sold 2,000 shares at $15.51 ($29K) on 2023-03-27, disclosed to the SEC on 2023-03-29.
Scheduled sale ($29k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.63 | 1,800 | $26K | 89.5% |
| 2 | $15.51 | 200 | $3K | 10.5% |
| Total | $14.72 avg | 2,000 | $29K | 100% |
| Filing → |
| TRDA | SELL | 2024-05-20 | $45K | — | Filing → |
| TRDA | SELL | 2024-02-20 | $15K | — | Filing → |
| TRDA | SELL | 2024-01-18 | $16K | — | Filing → |